Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Phase 1

Completed

• Conditions: Neuropathic Pain From Lumbosacral Radiculopathy
• Interventions: Drug: KLS-2031; Other: Placebo

• Registration Number: NCT04238793
• Lead Sponsor: Kolon Life Science

Brief Summary

Escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031

Detailed Description

This is a first-in-human (FIH), multicenter, double-blind, placebo-controlled, parallel-group, escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031 administered by transforaminal epidural injection to subjects aged 18 to 75 years with neuropathic pain due to LSR.

Study Timeline

• Study First Submitted: 2019-12-24
• Study First Submitted QC: 2020-01-20
• Study First Posted: 2020-01-23
• Study Start: 2020-04-16
• Primary Completion: 2023-10-18
• Study Completion: 2023-10-18
• Status Verified: 2024-07
• Last Update Submitted: 2024-07-25
• Last Update Posted: 2024-07-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

To participate in the study, subjects must have met the following criteria at Visit 1 (Screening,

Day -56 to Day -15):

1. The subject signed a written informed consent for study participation including the 1-year double-blind treatment period and 1-year, open-label, long-term extension period.

   Informed consent must have been obtained before any screening activities are conducted.

2. The subject, male or female, must have been between the ages of 18 and 75 years, inclusive.

3. The subject must have had a body mass index of ≤35 kg/m².

4. The subject must have had a diagnosis of pain due to LSR, with all of the following characteristics:

   1. The subject perceived pain in 1 or both lower limbs at areas that are consistent with the area innervated by the lumbar 4 or 5 or sacral 1 (L4, L5, S1) nerve roots, with or without other sensory symptoms in the affected areas (typically, the pain may have been perceived in the buttock, thigh, calf, leg, foot, or toes). If both limbs were affected, pain had to be asymmetrical (ie, pain worse in 1 limb).
   2. Pain in the leg radiated to below the knee.
   3. Pain in the leg was worse during rest and/or at night and not solely present upon walking.
   4. The history of the pain suggested that the cause of the LSR was due to the injury of the lumbosacral nerve root(s) by degenerative disease of the vertebrae in the lumbosacral spine or associated soft tissues (including the intervertebral discs).
   5. The duration of the pain since onset was ≥6 months.
   6. Based on clinical history, the intensity of the neuropathic (leg) pain had been stable during the 4-week period before screening (the pain may have fluctuated and may have been worse at night or at rest but was present on most days of the week).

5. Pain in the leg (worse affected leg) was worse than pain in the back.

Exclusion Criteria

Subjects were excluded from the study if 1 or more of the following criteria were applicable:

1. The subject had:

   1. Neuropathic pain due to causes other than that specified in the inclusion criteria (eg, postherpetic neuralgia; painful diabetic neuropathy; mononeuritis multiplex; central poststroke pain; spinal abscess, infection, hematoma, spondylolisthesis with displacement, or malignancy; phantom limb pain; peripheral neuropathy due to alcoholism, malignancy, HIV, syphilis; drug abuse; vitamin B12 deficiency; hypothyroidism; liver disease; toxic exposure).
   2. Radicular pain at more than 1 spinal level, unstable spine, spondylolisthesis (>Grade 1), spondylolysis, caudal equina syndrome, arachnoiditis, progressive neurological deficit, moderate to severe central spinal canal stenosis (congenital or acquired) from other origins, vertebral compression fracture(s).
   3. Pain that was associated with a substantial somatic pain component in lower limbs or other parts of the body apart from the back (eg, non-neuropathic/musculoskeletal pain) or more than 1 cause or potential cause for pain symptoms in low limbs.
   4. Any painful concurrent rheumatic disease such as, but not limited to, fibromyalgia, rheumatoid arthritis, or osteoarthritis that in the investigator's opinion would have prevented the subject from reliably delineating or assessing his/her pain due to LSR. Note: Any question regarding the acceptability of the etiology of the neuropathic pain was to be discussed with the medical monitor.

2. Had lumbar stenosis with pain present solely upon walking. Presence of lumbar narrowing on MRI was acceptable if the pain was not solely present upon walking.

3. In the investigator's opinion, the subject was unable to reliably delineate or assess his/her own pain by anatomical location/distribution (eg, the subject could not reliably tell the difference between his/her back pain and lower limb pain and could not rate the intensity of each separately).

4. The subject had pain in the lower limbs solely upon walking and not at rest.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1	KLS-2031	Dose 1 (low dose: 1×1011 VG/500 μL solution) or Placebo
Cohort 1	Placebo	Dose 1 (low dose: 1×1011 VG/500 μL solution) or Placebo
Cohort 2	Placebo	Dose 2 (medium dose: 1×1012 VG/500 μL solution) or Placebo
Cohort 3	Placebo	Dose 3 (high dose: 1×1013 VG/500 μL solution) or Placebo
Cohort 2	KLS-2031	Dose 2 (medium dose: 1×1012 VG/500 μL solution) or Placebo
Cohort 3	KLS-2031	Dose 3 (high dose: 1×1013 VG/500 μL solution) or Placebo

Primary Outcome Measures

Name	Time	Method
The safety and tolerability of KLS-2031	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52	Frequency and nature of AEs, laboratory test results, vital sign measurements, physical and complete neurological examinations, and 12-lead electrocardiograms (ECGs)

Secondary Outcome Measures

Name	Time	Method
Long-term safety and tolerability of KLS-2031	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 78, Week 104	Frequency and nature of AEs, laboratory test results, vital sign measurements, physical and complete neurological examinations, and 12-lead ECGs
Time (number of weeks) to ≥30% and ≥ 50% reduction from baseline in the average daily pain score (PI-NRS)	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Amount of rescue medication used (in terms of dosage/day)	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52
Time to treatment failure	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52	, defined as the day and time a subject starts pain medication other than acetaminophen for the treatment of neuropathic pain
Change from baseline in weekly mean of the average daily pain score	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104	calculated as the average of the subject's last 4 available PI-NRS daily scores in the week before the study visit
Change from baseline in the modified Modified Roland-Morris Disability Questionnaire (RMDQ) scores (back pain and leg pain)	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Local safety and tolerability (including AEs, clinical laboratory parameters, and physical examination) of administration by transforaminal epidural injectionepidural injection as measured by the occurrence of injection site reactions	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52	The occurrence of injection site reactions
Change from baseline in Galer Neuropathic Pain Scale (Galer NPS)	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Change from baseline in the Simple Profile of Moods States (POMS) - 2 Short Form total score and domain scores	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Assessment of suicidality	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52	using the Columbia Suicide Severity Rating Scale (C-SSRS)
Number and percentage of subjects who have ≥30% and ≥50% reduction from baseline in the average daily pain score (PI-NRS)	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Number and percentage of subjects who are much improved or very much improved from baseline	Week 12, Week 26, Week 52, Week 104	based on the Patient Global Impression of Change (PGIC)
Change from baseline in Daily Sleep Interference Scale (DSIS) score	Week 1, Week 2, Week 4, Week 12, Week 26, Week 52, Week 104
Change from baseline in the Short Form-36 v2 (SF-36v2) score	Week 12, Week 26, Week 52, Week 104

Trial Locations

Locations (1)

Kolon Investigative Site : CenExel JBR; 🇺🇸 Salt Lake City, Utah, United States